Both cagrilintide and retatrutide have specific contraindications and populations requiring special consideration [19]: Absolute Contraindications: Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Previous severe allergic reaction to either compound Pregnancy or breastfeeding (insufficient safety data) Relative Contraindications Requiring Careful Evaluation: History of pancreatitis Severe gastroparesis or GI motility disorders Active gallbladder disease Severe renal impairment History of eating disorders Concurrent use of other appetite suppressants The cagrilintide dosage with retatrutide combination would carry all contraindications for both compounds, plus additional caution due to unknown interactions
The most commonly reported adverse effect of Semaglutide is nausea, especially during the early weeks or after a dose increase
Secondary carnitine deficiency: Develops as a consequence of another condition, such as chronic kidney disease, liver disease, or certain intestinal disorders that impair carnitine absorption
This is likely due to glutathione's role in cellular energy production and its ability to reduce cellular stress
Caroline Messer expresses concern that many clinicians prescribing GLP-1 drugs are not endocrinologists or trained in obesity medicine
Arterial and venous ammonia concentrations in the diagnosis of canine hepatoencephalopathy
.webp)
